Oncology Times

Skip Navigation LinksHome > Collections > Multiple Myeloma

Multiple Myeloma

Creator:   Editor
Created:   8/7/2010
Contains:  88 items
Articles about Multiple Myeloma

Show
Previous of 1 Next

Debate: No One-Size-Fits-All in Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Invariant Natural Killer T Cells & Allogeneic Stem Cell Transplantation

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves Kyprolis Combo Therapy for Relapsed/Refractory Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

POINT-COUNTERPOINT: HDAC Inhibitors Hit a Single, Not a Home Run, Against Myeloma

Free Access
PDF
+ Favorites
Request Permissions

POINT-COUNTERPOINT: To Maintain or Not to Maintain in Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Paradigm Shift in Myeloma Care

Free Access
PDF
+ Favorites
Request Permissions

Stem Cell Transplant in Myeloma: Necessity or Choice?

Free Access
PDF
+ Favorites
Request Permissions

Best Myeloma Abstracts from ASH 2015

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves Empliciti & Ninlaro for Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: How to Fit the Three New Drugs into Clinical Practice: NEW: Earn CME by Reading This Article!

Free Access
PDF
+ Favorites
Request Permissions

Best Multiple Myeloma Research, 2015

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves Darzalex for Previously Treated Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Excitement about Monoclonal Antibodies

Free Access
PDF
+ Favorites
Request Permissions

FDA Priority Review to CLL and Myeloma Drugs

Free Access
PDF
+ Favorites
Request Permissions

Myeloma-Related Renal Failure on the Decline

Free Access
PDF
+ Favorites
Request Permissions

Priority Review to Two Drugs for Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Daratumumab Receives FDA Priority Review for Double-Refractory Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Myeloma Exome Analysis Uncovers Clinical Insights

Free Access
PDF
+ Favorites
Request Permissions

First Report of Success of T-Cell Therapy in Myeloma

Free Access
PDF
+ Favorites
Request Permissions

POINT-COUNTERPOINT: Best Maintenance Therapy for Patients with Newly Diagnosed Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Refractory Myeloma: A Monoclonal Antibody for First Time Has Single-Agent Activity

Free Access
PDF
+ Favorites
Request Permissions

First Monoclonal Antibody for Myeloma Shows Increases in PFS and Overall Response

Free Access
PDF
+ Favorites
Request Permissions

Myeloma Debate: Should Consolidation Therapy & MRD Testing be Used for Monitoring & Treatment?

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: New Scoring System Better IDs Frail vs. Fit Elderly Patients—Opens Door to Improved Decisions about Treatment Options

Free Access
PDF
+ Favorites
Request Permissions

Cancer-Related Crowdsourcing and Crowdfunding Move beyond the Basics—with Many Active Projects Ongoing in Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Warning that Patients Having Hematopoietic Stem Cell Transplants Appear to Have More Fractures

Free Access
PDF
+ Favorites
Request Permissions

FDA Grants Priority Review to Kyprolis for Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

New Data Provoke Screening Debate about MGUS and Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

iPad Extras: Audio Reports from the ASH Annual Meeting

Free Access
PDF
+ Favorites
Request Permissions

High-Risk Smoldering Myeloma: To Treat or Not to Treat Still a Question

Free Access
PDF
+ Favorites
Request Permissions

Key Myeloma Takeaways from ASH 2014

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Should Complete Remission, However Strictly Defined, Be the Goal for All Patients?

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Oral Proteosome Inhibitor Ixazomib Moves from Induction to Maintenance

Free Access
PDF
+ Favorites
Request Permissions

Anti-CD38 Monoclonal Antibodies Called Next ‘Blockbuster’ Drug Class for Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Crowds ASPIRE to Hear Myeloma Report

Free Access
PDF
+ Favorites
Request Permissions

Best Myeloma Research of 2014

Free Access
PDF
+ Favorites
Request Permissions

‘Missing Piece of Myeloma Puzzle’ Defined

Free Access
PDF
+ Favorites
Request Permissions

AACR Conference Highlights Promising Early Research on Blood Malignancies

Free Access
PDF
+ Favorites
Request Permissions

Debating Upfront Transplant in Multiple Myeloma

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Panobinostat in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival in Patients Who Have Disease Relapse

Free Access
PDF
+ Favorites
Request Permissions

Hematological Malignancy Takeaways from ASCO 2014

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Debating the Optimal Approach for Patients with Relapsed/Refractory Disease

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Whole Exome Sequencing Finds Progression-Related Molecular Changes

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Pomalidomide + Dexamethasone Promising for Relapsed/Refractory Disease

Free Access
PDF
+ Favorites
Request Permissions

High-Risk Myeloma: Maintenance Pros & Cons

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: ‘Old Rules’ No Longer Apply

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: ‘Conditional Survival’ Concept Identifies Patients with Extended Life Expectancy

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Front-Line for Continuous ‘Rd’

Free Access
PDF
+ Favorites
Request Permissions

For CLL and Myeloma Patients, MRD Remains Uncertain Goal

Free Access
PDF
+ Favorites
Request Permissions

ASH Annual Meeting: Key Myeloma Takeaways

Free Access
PDF
+ Favorites
Request Permissions

Best Myeloma Research 2013

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Should Alkylators Be Used Upfront in Transplant-Ineligible Patients?

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Is Maintenance Therapy Needed; and If So, with What?

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Promising Treatment Updates for Patients with Relapsed/Refractory Disease

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: What the Expected Redefinitions Mean for Patient Care

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Debating the Best Maintenance Strategy after a Post-Transplant Good Response

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Recommendation to Switch to Second-Generation Novel Agents After Failure of Frontline Resistance

Free Access
PDF
+ Favorites
Request Permissions

Smoldering Multiple Myeloma: When to Treat, When to Stick with Monitoring Alone

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: ‘Continued Treatment’ Not Maintenance

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: The Pros and Cons of Transplantation

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: New Agents Found Highly Active and Better Tolerated

Free Access
PDF
+ Favorites
Request Permissions

ASH Annual Meeting: Key Myeloma Takeaways

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: For Bone Disease, Current Recommendation Remains to Use Zoledronic Acid, Not Denosumab

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Second Malignancies Can Be Innate and Drug Induced

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Novel Agents Combined with Standard Therapy Show Promise for Bortezomib-Refractory Patients

Free Access
PDF
+ Favorites
Request Permissions

FDA Approvals for Supplemental NDA for Velcade for Myeloma and Mantle Cell Lymphoma, and Picato Gel for Actinic Keratosis

Free Access
PDF
+ Favorites
Request Permissions

Best Myeloma Research of 2011

Free Access
PDF
+ Favorites
Request Permissions

Key Myeloma Takeaways from ASH

Free Access
PDF
+ Favorites
Request Permissions

How Do I Treat Patients with Newly Diagnosed Multiple Myeloma Who Are Not Eligible for Clinical Trials?

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Early Start for Zoledronic Acid Further Reduces Risk of Skeletal Events

Free Access
PDF
+ Favorites
Request Permissions

Relapsed Myeloma: Subcutaneous Bortezomib as Good as Intravenous

Free Access
PDF
+ Favorites
Request Permissions

ASH ANNUAL MEETING: For Myeloma Transplantation, Tradeoffs Result in Similar Outcomes for Tandem Autologous vs Auto-allogeneic Procedures

Free Access
PDF
+ Favorites
Request Permissions

ASH ANNUAL MEETING: Myeloma Phase III CALGB 100104 Study: Lenalidomide Maintenance Doubles Time to Disease Progression

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: How Many Drugs in a Multi-Drug Regimen?

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Not All CRs Are Alike

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Allogeneic Transplant Has Role in Salvage Therapy

Free Access
PDF
+ Favorites
Request Permissions

Nurses Urged to Take on Greater Role with Multiple Myeloma Patients

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Novel-Agent Treatment Catching Up to Transplant Regimens

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Building on Len-Dex for Relapsed/Refractory Disease

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Bone-Targeted Therapy Results in 5-Month Longer Survival: MRC IX Study Results from European Hematology Association Congress

Free Access
PDF
+ Favorites
Request Permissions

From ASCO Annual Meeting: Maintenance Therapy Helping to Reduce Relapse Rates in Multiple Myeloma, Follicular Lymphoma

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Pomalidomide Found Active in Heavily Pretreated Patients

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: New Drug Roundup

Free Access
PDF
+ Favorites
Request Permissions

Myeloma: Modified VISTA Induction Regimen Found Safe for Elderly Patients

Free Access
PDF
+ Favorites
Request Permissions

Transplantation in Multiple Myeloma: Research Roundup

Free Access
PDF
+ Favorites
Request Permissions

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Duration: 3:52
Oncology Times 

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.

Download (906 KB)
+ Favorites

Program 2, Sunday Dec. 6

Creator: Peter Goodwin
Duration: 19:00
Oncology Times 

George Canellos, What’s hot from the ASH Plenary Session.

Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commentary Dr. Canellos and Jesus San-Miguel, also of Salamanca, and Richard Van Etten of Tufts University.

Steven Devine of Ohio State University on T-cell depletion to avoid GVHD in AML; commentary from Dr. Canellos and Armand Keating of the University of Toronto.

Download (3.91 MB)
+ Favorites

Program 4, Day 4, Monday Dec 8

Creator: Peter Goodwin
Duration: 22:07
Oncology Times 

Prof Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leukaemia. ASH President Nancy Berliner of Brigham & Women's Hospital adds her thoughts.

Jorge Cortes of M. D. Anderson Cancer Center on three different ASH papers by his group looking at alternatives to standard imatinib in CML. Jane Apperley of Hammersmith Hospital and Imperial College London, reflects on these, and discusses strategies for dealing with imatinib resistance.

OT Broadcast News Scientific Editor George Canellos of Dana-Farber Cancer Institute on what some were jokingly calling a re-run of World War II that took place in the Non-Hodgkin’s Lymphoma session: R-CHOP 14 vs R-CHOP 21 in elderly patients with diffuse large B-cell lymphoma.

Andrzej Jakubowiak of the University of Michigan discusses a 4-drug regimen to treat newly diagnosed multiple myeloma....Ruben Niesvizky of Weill Cornell Medical College in New York City on the novel proteasome inhibitor carfilzomib, used in combination with lenalidomide and dexamethasone to treat relapsed or refractory multiple myeloma. OT interviewers: Peter Goodwin and Sarah Maxwell.

Download (4.89 MB)
+ Favorites
Show
Previous of 1 Next
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.